Background Optic pathway gliomas (OPGs) are common pediatric brain tumors that pose significant clinical challenges with regard to predicting which tumors are likely to become symptomatic and require treatment. These tumors can arise sporadically or in the context of the inherited cancer predisposition syndrome neurofibromatosis type 1 (NF1). Few studies have suggested biological or imaging markers that predict the clinical course of this disease. Objective In this cross-sectional study, we hypothesized that the clinical behavior of OPGs in children can be differentiated by diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI. Materials and methods A total of 27 children with OPG were studied using DW and DCE MRI protocols. Diffusivity and permeability were calculated and correlated with the clinical behavior the OPG.
Introduction
Low-grade gliomas are one of the most common brain tumors seen in the pediatric population. The majority of these tumors are classified by the World Health Organization as grade I pilocytic astrocytomas, and they are most commonly found in the cerebellum and along the optic pathway [1] . Compared to low-grade gliomas involving the cerebellum, where surgical resection is often curative, surgery plays a limited role when these tumors develop within the optic pathway. Most of these young children are evaluated by serial ophthalmological examinations, which can be challenging in very young children; those with declining visual acuity are treated with chemotherapy. For these reasons, it would be desirable to develop surrogate indicators that predict optic glioma growth to select children most likely to benefit from close observation.
Optic pathway gliomas (OPGs) arise sporadically or in the context of the tumor predisposition syndrome neurofibromatosis 1 (NF1), or von Recklinghausen disease. NF1 affects approximately 1 in 2,500 individuals worldwide [2, 3] and is the most common genetic cause for these tumors. Of individuals with NF1, 15-20% will develop an optic glioma, usually within the first decade of life (mean age at presentation of 4.5 years) [4, 5] . NF1-associated OPGs are histologically identical to pilocytic astrocytomas that occur in individuals without NF1 [6] . However, some reports have suggested that NF1-associated optic gliomas behave in a clinically less aggressive manner than those that occur in the general population [7] [8] [9] [10] .
Although OPGs are low-grade tumors, their clinical course is highly variable. Some children with OPG will exhibit progressive tumor growth and vision loss [11, 12] , while in other children with OPG with a similar appearance will spontaneously regress [13] [14] [15] [16] . Unfortunately, our current insights derive from studies on small numbers of subjects with various types of treatments, and no macroscopic or microscopic features have been identified that reliably predict a given patient's clinical course [7] . Thus, identifying children with OPGs that are likely to progress remains a major clinical problem. In this study, we hypothesized that advanced MR imaging methods, including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) imaging, might offer insight into this particular clinical management issue.
Materials and methods

Patients
A total of 27 children were identified from our clinical practice at St. Louis Children's Hospital (SLCH). Of these children, 14 had a clinical diagnosis of NF1 and were cared for by one of the investigators (D.H.G.), who directs the Neurofibromatosis Clinic at SLCH. Based upon established guidelines for the management of children with NF1 [17] , children in the NF program are examined clinically at least annually, and more frequently if clinically indicated. This study was performed in accordance with an approved Washington University IRB Human Studies protocol. All children enrolled in the study had been identified as having an OPG.
In this cross-sectional study, tumors were classified as either clinically aggressive or clinically stable. This classification was based upon two specific clinical features: decline in visual acuity and a need for therapeutic intervention. Clinically aggressive tumors were defined as those in children who had experienced a decline in their visual acuity significant enough (typically a reduction of two or more lines in visual acuity) that their treating neurooncology team (neurologist, oncologist and ophthalmologist) thought that they required treatment (surgery, chemotherapy, and/or radiation). If the patient's treating physicians determined that the patient required therapeutic intervention for any reason other than visual decline, tumors in these children were also classified as clinically aggressive. Children who had asymptomatic or clinically nonprogressive symptomatic OPG and did not require therapeutic intervention were classified as clinically stable. This classification was based upon the patient's status at the time of his or her last recorded medical visit during the time course of the study (10 months).
MRI protocol
All children were subject to at least one MR imaging evaluation during the course of the study. All examinations were performed at SLCH with sedation on either a 1.5-T system (Sonata; Siemens, Erlangen, Germany) or a 3-T system (Trio; Siemens, Erlangen, Germany) using a dedicated head RF coil. The clinical protocol included multiplanar, multiweighted imaging of the orbits and optic pathway. The diffusion and DCE sequences are described below.
DW and DCE imaging
The diffusion sequence consisted of single-shot multisection spin-echo EPI with FOV of 230×230 mm 2 , inplane resolution of 1.9×1.9 mm 2 interpolated to 256×256 for display and analysis, TR of 5,000 ms, and TE of 85 ms. Three orthogonally oriented DW images (diffusion sensitivity, b=1,000 s/mm 2 ), and a reference T2-weighted intensity image (b = 0 s/mm 2 ) were obtained at each transverse section. The DW acquisition and reconstruction and subsequent computation of ADC maps required about 2 minutes. DCE MRI was performed using a T1-weighted 3-D FLASH sequence (TR 30 ms, TE 6 ms). A matrix of 128× 128×16 was used to achieve a resolution of 1×1×3 mm 3 . Each 3-D image was acquired in less than 1 min. A precontrast variable flip angle experiment (flip angles of 10°, 15°, and 25°) was performed to estimate T1 on a voxel-by-voxel basis. A bolus of gadolinium-based contrast agent, 0.1 mmol/kg, was injected, and dynamic scanning was performed for at least 6 min using the T1-weighted 3-D sequence described above.
Identification of tumor volumes and regions of interest
A region of interest (ROI), in this case the presumed OPG tissue, was identified for each patient using T1-weighted contrast-enhanced images that were simultaneously loaded with the DW and DCE sequences. Images were coregistered using Intelli-link software and the tumor boundaries identified manually on the anatomic T1-weighted contrastenhanced images. On all serial slices containing tumor tissue, a free-hand ROI was drawn to circumscribe the entire tumor area (all areas determined to be tumor by the collaborating neuroradiologist excluding cyst and CSF spaces). The tumor volume in each slice was computed by multiplying the area of the ROI by the slice thickness and the total tumor volume was then computed by serially adding the volumes measured for each slice.
Processing of diffusion and DCE data
For processing, diffusion (ADC) maps were loaded into the Synapse software system (Fuji Medical Systems, Roselle, IL). We used the Intelli-link feature of the Fuji Synapse, which automatically cross references a selected voxel in the reference T1-weighted images with the target voxel in the ADC map. This allowed us to precisely outline, using a free-hand ROI definition technique, the margins of the tumor on the anatomical image and apply that region definition to the diffusion map. We used T2-weighted images for comparison to avoid frankly cystic areas and those containing CSF. If the ADC images were distorted at the skull base, the target ROI was modified to conform to the tumor margins and exclude CSF. For each slice, the ROI used for volumetric measurement was overlaid on the ADC map and mean ADC values were computed for the overall tumor volume. DCE data were analyzed via a standard Patlak analysis [18, 19] using customized Matlab-based (MathWorks, Natick, MA) software. The Voxa analysis package in Matlab allows voxel-by-voxel region definition. Raw DCE data were loaded into Voxa, and the ROIs used for ADC analysis were used to guide region definition for DCE analysis. The DCE regions, however, excluded nonenhancing voxels; thus the DCE regions tended to be smaller than the ADC regions.
Voxels in both the tissue and blood ROIs with intensities less than the standard deviation of a selected noise region were excluded from the calculations. Values of the tissue permeability-surface area product, K PS (ml/min per 100 cm 3 of tissue), were calculated on a voxel-by-voxel basis using standard equations. In performing this analysis, nonenhancing tumor voxels having a negative or zero slope and blood vessels whose initial slope was greater than 0.45 were excluded. Average values of K PS for each tumor ROI are reported.
Statistical analysis
Values for tumor volume, mean diffusivity, and mean permeability (K PS ) were calculated for each enrolled patient in a blinded fashion. Data were then unblinded and imaging data values were compared with the inheritance pattern (sporadic versus NF1-associated) and with clinical aggressiveness (requiring treatment: yes or no). Mean and range values were compared for each of these groups and Student's t-tests and chi-squared analysis were performed to compare imaging data values for individual groups.
Results
A total of 27 children with OPG having correlative DW and DCE imaging were enrolled in the study over 10 months between November 2004 and August 2005 (Table 1) . Of these 27 children, 14 met the diagnostic criteria for NF1, and 13 had a sporadic OPG without clinical features of NF1. All children had tumors located within the prechiasmatic optic nerves or the optic chiasm. Three children had chiasmatic tumors that extended into the hypothalamus ( Table 2 ). The tumors were classified as clinically stable in 11 children, and as clinically aggressive in 16 children who required treatment with chemotherapy (n=10), radiation (n=3) or surgical resection (n=3) during the study or prior to enrollment. Two initially asymptomatic children devel- oped clinical progression and required treatment during the study. These tumors were classified as clinically aggressive. Nine children had more than one imaging examination during the research study, with a mean interval of 3.1 months between MRI scans. For the three children who underwent surgical resection, pathology confirmed pilocytic astrocytoma. Biopsy was not performed for tissue diagnosis in any of the other children in this study, as this is not a part of the routine treatment for children with OPG. In no children were there indications that the tumors were higher-grade gliomas. Mean diffusivity, permeability, and tumor volume were calculated for the tumor ROI for each patient at each imaging time point. For the group as a whole, OPGs had a mean diffusivity of 1.39 μm 2 /ms (range 1.0-2.35 μm 2 /ms) and a mean permeability (K PS ) of 2.10 ml/min per 100 cm 3 of tissue (range0.23-6.37 ml/min per 100 cm 3 ). Both sporadic and NF1-associated OPGs had a broad range of diffusivity and permeability values (Fig. 1) . The two tumors that progressed clinically during the course of the imaging study did not differ significantly in either their mean diffusivity or permeability from the tumors that did not progress.
NF1 status was strongly correlated with clinical aggressiveness. Children with sporadic OPGs exhibited more clinically aggressive disease: 75% of children with clinically stable disease met the diagnostic criteria for NF1, while the remaining 25% of children with clinically stable disease had a sporadic tumor. Correspondingly, 71% of children with clinically aggressive disease had a sporadic tumor; 29% of children with clinically aggressive disease had NF1. These data are summarized in Table 1 (chisquared=5.78; P<0.05).
Mean permeability values correlated with clinically aggressive disease. These clinically aggressive OPGs had a significantly higher mean permeability value (2.24 ml/min per 100 cm 3 ) than the clinically stable tumors (1.38 ml/min per 100 cm 3 ; P=0.05). While clinically aggressive tumors had Fig. 1 Sporadic and NF1-associated OPGs have a wide range of permeability (a) and diffusion (b) values, and there is no significant difference in either between these two groups. The few children whose OPG progressed during the course of the study (closed boxes) cannot be separated from the remainder of children whose OPG were clinically stable over the course of the study (closed triangles) All tumors were located in the prechiasmatic or chiasmatic regions. Three children had tumors that also extended into the hypothalamus. Tumor location was not found to be a statistically significant factor with respect to outcome. a wide range of permeability values (0.23-6.37 ml/min per 100 cm 3 ), nearly half the clinically aggressive tumors (47%) had a permeability value of >2.0 ml/min per 100 cm 3 . No clinically stable tumors had a permeability value of >2.0 ml/min per 100 cm 3 . These results are displayed graphically in Fig. 2 . Further supporting the observed correlation between tumor aggressiveness and vascular permeability, sporadic tumors classified as clinically aggressive had a significantly higher mean permeability value (2.77 ml/min per 100 cm 3 ) than those classified as clinically stable (P<0.05).
In contrast, mean diffusivity values did not correlate with either clinical aggressiveness or with the presence of NF1, and there was no significant correlation between tumor size and either mean diffusivity or permeability. Correspondingly, there was no correlation between permeability and mean diffusivity for any individual tumor ROI.
Discussion
Optic pathway gliomas, whether associated with NF1 or not (sporadic), are difficult tumors to manage. These gliomas tend to grow slowly, their clinical course is variable, and there are no clinical, imaging, or pathological markers that accurately predict tumor progression. Once vision is compromised, therapeutic intervention often does little to reverse existing visual loss. Consequently, it is critical to identify children most likely to progress early during the course of their disease, preferably prior to clinical deterioration, so that vision-saving treatment can be initiated. In this study, we hypothesized that advanced imaging techniques, including diffusion-weighted and dynamic contrastenhanced MR imaging, might be useful tools for predicting the clinical behavior of optic glioma.
MR imaging has provided important insights germane to the management of a variety of cancers, including brain tumors. One of the clear advantages of MRI is its ability to enable detailed anatomic localization of a tumor and delineation of its size. However, our study as well as previous studies found no correlation between tumor size and clinical behavior.
DW imaging is sensitive to the microstructure of biological tissues on a distance scale of 1-10 µm and, as such, reflects changes in tumor cell density. DW imaging has been used to measure the mean diffusivity of water in vivo (i.e., apparent diffusion coefficient or ADC). Elegant studies [20] [21] [22] have demonstrated that changes in the ADC of water correlate with tumor response to cytotoxic therapy both in rat models of malignant gliomas and in human malignant brain tumors. Previous studies in children with pilocytic astrocytomas have shown mean ADC values of 1.3-2.09 μm 2 /ms [23-25], which is comparable to our mean value of 1.41 μm 2 /ms. Similarly, a previous study found a mean ADC value of 1.18 μm 2 /ms in a 1-year-old child with NF1 and an extensive optic nerve/chiasmatic optic glioma [26] . However, we found that ADC did not distinguish between clinically stable and clinically aggressive OPG. This most likely reflects the low cellularity of these tumors and their relatively modest proliferative indices.
DCE-MRI is an imaging method with the ability to measure vascular permeability. Increased vascular permeability has been observed in gliomas, particularly malignant gliomas [27] , and DCE imaging is being used in clinical trials of antiangiogenic therapies for malignant brain tumors. The usefulness of DCE methods for assessing the clinical behavior of lower-grade tumors, such as OPG, has not been clearly established. In our study, we found a statistically significant correlation between increased DCE values and the clinical behavior of OPG. It is worth noting that pilocytic astrocytomas are highly vascular tumors, similar to high-grade glioma. Moreover, in a mouse model of NF1 optic glioma, vascular endothelial proliferation has been shown to correlate with tumor growth in vivo, providing supportive evidence for our findings in pediatric OPG [28] .
Previous studies have suggested that children with NF1-associated OPG exhibit a more indolent course than those with sporadically occurring tumors [6] . Our study population included a good mix of children with NF1-associated versus sporadic tumors, and a range of children with clinically stable and clinically aggressive disease phenotypes. Similar to others, our data support the claim that NF1 children with OPG have a comparatively less clinically aggressive disease course [7] [8] [9] [10] .
Although our conclusions are limited by the relatively small sample size, this study was intentionally designed as a cross-sectional study, involving a cohort of children with OPG cared for at a single institution over a relatively short time. More than half of these children had already progressed clinically, and many had undergone treatment with chemotherapy, radiation, or surgery. In this regard, only two children had evidence of clinical progression during the course of the study. It is possible that treatment, including corticosteroid therapy, affected the imaging results, particularly for diffusion and perfusion imaging [20, 29, 30] . However, none of the children in our study was receiving corticosteroid therapy at or near the time of MR imaging.
Because of the suprasellar location of many of the lesions, susceptibility effects from the sphenoid sinus can potentially distort EPI-based DW images. This could have complicated quantitative analysis of ADC, owing to the presence of magnetic field gradients; however, after careful review, this distortion was a significant factor in only one patient in the study, and in this particular case the data presumed to be confounded by artifact were excluded from the analysis.
Despite these caveats, our study provides important new information regarding the potential utility of DCE imaging in the management of OPG. Future studies will be required on larger cohorts of children with OPG to validate these findings. In particular, prospective studies using DCE and DWI will be critical to confirm the prognostic specificity of our findings and to distinguish tumor physiology from changes associated with consequences of therapeutic intervention. If non-invasive biomarkers, such as ADC and permeability, prove useful in identifying a subset of children whose tumors are likely to be more aggressive and cause visual deterioration, early identification and intervention could be key in minimizing permanent visual compromise in this challenging pediatric patient population.
Conclusion
The proposed correlation between diffusivity and treatment response/clinical behavior seen in children with malignant gliomas cannot be directly applied to children with lowgrade OPG. However, our study suggests that children whose OPG has a high permeability (K PS >2.0 ml/min per 100 cm 3 ) are at increased risk of clinical progression. Based on these preliminary findings, such children warrant close follow-up, as their risk of symptomatic progression might be increased. 
